TSUMURA & CO.
Business Results for Fiscal 2012
May 10, 2013
Font Size
sm
md
lg
TSUMURA & CO.
Business Results for Fiscal 2012
President, Representative Director
Terukazu Kato
from the beginning
Business Results for Fiscal 2012
presenter :
President, Representative Director
Terukazu Kato
Strategic Positioning of Fiscal 2012
Prescription Kampo Product Market Trends
Business Results for Fiscal 2012
Consolidated Performance for Fiscal 2012, Ending March 31, 2013
Key Points in Fiscal Performance
Top 10 Kampo Products by Sales Amount
Factors in Increase / Decrease of Operating Profit
Analysis of Sales Cost Ratio
Analysis of Inventories Increase
Addressing Strategic Issues and Progress Status
Expanding Prescription Kampo Product Market in Japan
MR Activities
Growth in Physicians Prescribing Kampo Medicine
Strengthening Scientific Evidence Formation Efforts with New Organization
Evidence Building for Drug Fostering Program Products(DB-RCT & Safety)
Digestive Disease Week (DDW) Kampo-Related Presentation Topics
Progress of TU-100 Clinical Trials in the United States
Progress on TU-100 FDA Requirements
Progress with Production Cost Structure Reform
Domestic Crude Drug Cultivation Bases
Stability of Crude Drug Prices
Capital Investment Plan
Return of Profits to Shareholders
FY2013 (Year Ending March 2014)Performance Forecasts
FY2013 (Year Ending March 2014) Performance Forecasts
TSUMURA & CO.
Presentation File(PDF 1.2 MB)
Revised version of presentation slidecontaining the updated number of DDW abstracts is available for download.